Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.

MLA

Ravandi, Farhad, et al. “Prognostic Significance of Alterations in IDH Enzyme Isoforms in Patients with AML Treated with High-Dose Cytarabine and Idarubicin.” Cancer, vol. 118, no. 10, May 2012, pp. 2665–73. EBSCOhost, https://doi.org/10.1002/cncr.26580.

APA

Ravandi, F., Patel, K., Luthra, R., Faderl, S., Konopleva, M., Kadia, T., Brandt, M., Pierce, S., Kornblau, S., Andreeff, M., Wang, X., Garcia-Manero, G., Cortes, J., & Kantarjian, H. (2012). Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer, 118(10), 2665–2673. https://doi.org/10.1002/cncr.26580

Chicago

Ravandi, Farhad, Keyur Patel, Rajyalakshmi Luthra, Stefan Faderl, Marina Konopleva, Tapan Kadia, Mark Brandt, et al. 2012. “Prognostic Significance of Alterations in IDH Enzyme Isoforms in Patients with AML Treated with High-Dose Cytarabine and Idarubicin.” Cancer 118 (10): 2665–73. doi:10.1002/cncr.26580.